Jason Wittes
Stock Analyst at Roth Capital
(2.69)
# 1,678
Out of 5,174 analysts
58
Total ratings
49.06%
Success rate
3.97%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $7.54 | +430.50% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $328.51 | +38.81% | 11 | May 2, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $2.92 | +447.95% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $11.72 | +87.71% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $100.97 | -28.69% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $3.89 | +183.14% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $86.25 | +33.33% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $6.91 | +59.19% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.05 | +852.38% | 1 | Jun 26, 2024 | |
| LMAT LeMaitre Vascular | Reinstates: Buy | $100 | $109.99 | -9.08% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.80 | +177.78% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.38 | +2,240.70% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $22.11 | +239.21% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.75 | +87.23% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $86.32 | +39.02% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $178.69 | +15.28% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $200.52 | -27.69% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7.5 | $13.50 | -44.44% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $11.36 | +1,660.56% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $30.22 | -13.96% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $7.54
Upside: +430.50%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $328.51
Upside: +38.81%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $2.92
Upside: +447.95%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $11.72
Upside: +87.71%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $100.97
Upside: -28.69%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $3.89
Upside: +183.14%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $86.25
Upside: +33.33%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $6.91
Upside: +59.19%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.05
Upside: +852.38%
LeMaitre Vascular
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $109.99
Upside: -9.08%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $1.80
Upside: +177.78%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.38
Upside: +2,240.70%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $22.11
Upside: +239.21%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $11.75
Upside: +87.23%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $86.32
Upside: +39.02%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $178.69
Upside: +15.28%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $200.52
Upside: -27.69%
Mar 3, 2022
Initiates: Buy
Price Target: $7.5
Current: $13.50
Upside: -44.44%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $11.36
Upside: +1,660.56%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $30.22
Upside: -13.96%